Cytidine‐5′‐diphosphocholine (Citicoline): a pilot study in patients with non‐arteritic ischaemic optic neuropathy

Parisi, Vincenzo; Coppola, Gianluca; Ziccardi, Lucia; Gallinaro, Geltrude; Falsini, Benedetto

doi:10.1111/j.1468-1331.2008.02099.x

Cited by 44 publications

(43 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The choline deficiency could also be found in NAION patients, causing a deficiency of LysoPCs as products of choline; however, no significant differences of this molecule between patients and controls were found. Treatment with a precursor of choline, such as citicoline, has been used to improve consciousness levels in cerebral trauma and visual acuity in amblyopic patients (Fresina et al 2008) as well as to induce an improvement of the retinal and the visual pathway function in patients with glaucoma (Ottobelli et al 2013), although there are some controversial studies with regard to its efficiency (Davalos et al 2012;Parisi et al 2008).…”

Section: Metabolites As Potential Naion Biomarkersmentioning

confidence: 99%

Metabolomics in non-arteritic anterior ischemic optic neuropathy patients by liquid chromatography–quadrupole time-of-flight mass spectrometry

et al. 2014

View full text Add to dashboard Cite

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a rare ischemic disease that affects the optic nerve. Pathophysiology and mechanism of ischemia of NAION remain uncertain, so the aim of this work is to establish the first metabolic fingerprinting of patients with NAION to discover possible new biomarkers. Twenty-four patients, aged 39-85 years, diagnosed with NAION, after a sudden loss of vision, were recruited for the study. Plasma samples of patients and controls were fingerprinted with liquid chromatography coupled to quadrupole time-offlight by electrospray ionization, and obtained data were filtered, aligned and statistically analysed to identify new biomarkers. The identity of compounds that were found to be significant in class separation was later confirmed by obtaining the characteristic MS/MS spectra and online databases. In general, biochemical and metabolic profiles between patients and controls did not show profound differences, but NAION patients presented disturbances in the phospholipid composition which lead to reduced plasma values of LysoPCs. Altered levels of other metabolites, such as L-Palmitoylcarnitine, have been detected and could be considered as potential biomarkers.

show abstract

Section: Metabolites As Potential Naion Biomarkersmentioning

confidence: 99%

Metabolomics in non-arteritic anterior ischemic optic neuropathy patients by liquid chromatography–quadrupole time-of-flight mass spectrometry

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Potential neuromodulating and neuroprotective activity of citicoline has been effectively tried in patients with stroke [15], cognitive disorders [16,17] and Parkinson's disease [18,19,20]. In addition, a beneficial effect of citicoline has been described in a number of conditions affecting the visual system, like amblyopia [21,22,23,24] and nonarteritic ischemic optic neuropathy [25]. There are interesting findings concerning the use of citicoline in glaucoma [26,27,28,29,30,31].…”

Section: Introductionmentioning

confidence: 99%

Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?

et al. 2013

View full text Add to dashboard Cite

Purpose: To assess the effect of citicoline on visual field rates of progression in patients with progressing glaucoma. Patients and Methods: Forty-one patients with a diagnosis of progressing glaucoma received citicoline in oral solution for 2 years. Included were patients with a disease progression of at least -1 dB/year (at MD, mean deviation) for at least 3 years before entering the study despite controlled intraocular pressure (IOP). Patients were followed with 4 visual field examinations per year for 2 years. Results: At baseline, the mean rate of progression was -1.1 (±0.7) dB/year despite the fact that the IOP had been below 18 mm Hg for at least 3 years. At study inclusion, the mean IOP was 15.5 (±2.6) mm Hg and the mean MD was -9.2 (±6.7) dB in the worst eye. Starting from the first cycle of treatment with citicoline, the mean rate of progression significantly changed to -0.15 (±0.3) dB/year at the end of the study (p = 0.01). Conclusions: This study seems to indicate that supplementation with citicoline might significantly slow down glaucomatous rates of progression.

show abstract

“…The results were evaluated through electrophysiological examinations, leading to a significant improvement in the patients. Thus, it has been found that CDP choline can be used to treat patients with optic neuropathy [64].…”

Section: Discussionmentioning

confidence: 99%

“…A clinical study of 26 patients with optic neuropathy-administered cytidine diphosphate (CDP)-choline for about 6 months showed that CDP-choline is effective in regenerating optic nerves in these patients [64].…”

Section: Nucleotids and Cobalamin And Their Application For Regenerationmentioning

confidence: 99%

The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders

Manhães¹,

César²,

Justo³

et al. 2017

Peripheral Nerve Regeneration - From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based Therapies Deve

View full text Add to dashboard Cite

Studies have shown that the administration of drugs containing pyrimidine nucleotides, such as uridine triphosphate (UTP) and cytidine monophosphate (CMP), has been effective in pain-intensity reductions in patients with painful conditions as diabetic neuropathy, back pain, and cervical and trauma-compressive changes. The combination of pyrimidine nucleotides UTP and CMP is part of a peripheral neuro-regenerative process. Its pharmacological properties are stimulation of nerve cells proteins synthesis, nerve cell membranes synthesis, myelin sheaths synthesis, and neurite sprouting through P2Y receptors activation. Herein, chapter will be discussed the combination of UTP and CMP, and in some cases, the inclusion of cobalamin (B12 vitamin) that appears to have analgesic effects in neuropathic pain secondary to spine structural disorders assigned to a complex pharmacodynamic. The mechanisms involved can be both indirect (protein synthesis in nerve cells, myelin synthesis, synthesis of MBP, etc.) and direct (P2Y receptor stimulation).

show abstract

Cytidine‐5′‐diphosphocholine (Citicoline): a pilot study in patients with non‐arteritic ischaemic optic neuropathy

Abstract: Our results suggest a beneficial effect of oral Citicoline in NION.

Cited by 44 publications

References 47 publications

Metabolomics in non-arteritic anterior ischemic optic neuropathy patients by liquid chromatography–quadrupole time-of-flight mass spectrometry

Metabolomics in non-arteritic anterior ischemic optic neuropathy patients by liquid chromatography–quadrupole time-of-flight mass spectrometry

Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?

The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders

Contact Info

Product

Resources

About